Broad use of CRISPR-Cas12a (formerly Cpf1) nucleases 1 has been hindered by the requirement for an extended TTTV protospacer adjacent motif (PAM) 2 . To address this limitation, we engineered an enhanced Acidaminococcus sp. Cas12a variant (enAsCas12a) that has a substantially expanded targeting range, enabling targeting of many previously inaccessible PAMs. On average, enAsCas12a exhibits a twofold higher genome editing activity on sites with canonical TTTV PAMs compared to wild-type AsCas12a, and we successfully grafted a subset of mutations from enAsCas12a onto other previously described AsCas12a variants 3 to enhance their activities. enAsCas12a improves the efficiency of multiplex gene editing, endogenous gene activation and C-to-T base editing, and we engineered a high-fidelity version of enAs-Cas12a (enAsCas12a-HF1) to reduce off-target effects. Both enAsCas12a and enAsCas12a-HF1 function in HEK293T and primary human T cells when delivered as ribonucleoprotein (RNP) complexes. Collectively, enAsCas12a provides an optimized version of Cas12a that should enable wider application of Cas12a enzymes for gene and epigenetic editing.
and Moraxella bovoculi 237 (MbCas12a) were previously reported to recognize an increased number of PAMs in vitro 1 , our own findings ( Supplementary Fig. 1a ,b and see Supplementary Results) and those previously reported by others 16 have shown their activities to be less consistent and robust in human cells. Additionally, although two engineered AsCas12a variants (referred to as RVR and RR) were previously described that can recognize alternative TATV and TYCV PAMs 3 , respectively, many PAMs remain inaccessible to Cas12a. Thus, additional variants with expanded targeting capabilities are needed to enable applications requiring high targeting density and flexibility.
We used structure-guided protein engineering to attempt to expand the PAM recognition of Cas12a nucleases, focusing on AsCas12a because it has been widely used for genome editing and structural information was available 17, 18 . To do so, we engineered ten variants bearing single amino acid substitutions to positively charged arginine residues that might be expected to alter or form novel PAM proximal DNA contacts ( Supplementary Fig. 1c ). Four of the 10 variants we tested in human cells (S170R, E174R, S542R or K548R) displayed higher gene editing activities on sites with canonical and non-canonical PAMs relative to wild-type AsCas12a ( Supplementary Fig. 1d ,e, respectively). Testing of additional variants harboring combinations of these four substitutions on an expanded number of targets showed that two variants (E174R/S542R and E174R/S542R/K548R) exhibited the highest editing activities on sites with non-canonical PAMs while still retaining robust activities on a canonical PAM site ( Fig. 1a and Supplementary Fig. 1f ).
To comprehensively profile the PAM preferences of these AsCas12a variants, we optimized an unbiased in vitro PAM determination assay (PAMDA) similar to other previously described methods 3, 19 (see Supplementary Results, Supplementary Fig. 2a -i and Supplementary Table 1 ). Using the PAMDA, we defined the PAM preferences of wild-type AsCas12a and variants with all possible single, double and triple combinations of the E174R, S542R and K548R substitutions. Plots of the mean PAMDA log 10 k values on all 256 4-nt PAM sequences revealed that, as expected, targeting Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing Letters NATuRE BIOTECHNOlOgy with wild-type AsCas12a was most efficient against TTTV PAMs, and that E174R/S542R and E174R/S542R/K548R showed the most expanded PAM preferences among the seven variants tested ( Fig. 1b) . Strikingly, the E174R/S542R/K548R variant could target many PAMs including TTYN (TTTN/TTCN), VTTV (ATTV/ CTTV/GTTV), TRTV (TATV/TGTV) and others. Supplementary Fig. 2d ). c, Mean activity plots for AsCas12a variants on sites with noncanonical PAMs in human cells, where the black line represents the mean of 12 to 20 sites (dots) for each PAM class (see also Supplementary Fig. 3a Supplementary Fig. 3d ); mean shown for n = 20; NS, P > 0.05; ****P < 0.001 (Wilcoxon signed-rank, two-tailed; P values in Supplementary Table 8 ). e, Superimposition of the summaries of the human cell activities and PAMDA rate constants (k) for various targetable PAMs with enAsCas12a (E174R/S542R/K548R); mean and 95% confidence interval for human cell data are shown with black lines. Tier 1 PAMs exhibit greater than 20% mean targeting in human cells and a PAMDA k greater than 0.01; tier 2 PAMs meet a modest threshold of greater than 10% mean targeting in cells and a PAMDA k greater than 0.005 (see Supplementary Table 2 ). f, Calculation of the improvements in targeting range enabled by AsCas12a variants compared to wild-type AsCas12a, plotted as the number of PAMs per 100-base-pair (bp) window as determined by enumerating complete PAM sequences within the indicated sequence feature and normalizing for element size (see Methods). PAM sequences targetable by wild-type AsCas12a, TTTV; by RVR, TATV; and by RR, TYCV.
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Further characterization of the E174R/S542R and E174R/S542R/ K548R variants in human cells showed robust editing activities on 60 endogenous target sites with VTTV and TTCN PAMs, and less effective modification of 15 target sites with VTTT PAMs ( Fig. 1c and Supplementary Fig. 3a ). Consistent with the PAMDA results ( Fig. 1b ), we observed efficient gene editing on 12 target sites bearing TATV PAMs with the E174R/S542R/K548R variant but not with E174R/S524R ( Fig. 1c and Supplementary Fig. 3b ). Both variants modified five sites with TTTT PAMs that were inefficiently edited with wild-type AsCas12a ( Supplementary Fig. 3c ). These data show that our variants enable robust editing of sites with non-canonical VTTV, TTTT and TTCN/TATV PAMs that cannot be modified efficiently by wild-type AsCas12a (summarized in Fig. 1d ; see also Supplementary Figs. 1a and 3a-d).
Next, we examined the editing activities of the E174R/S542R/ K548R variant on 97 other sites in human cells bearing 28 additional PAMs identified as targetable by the PAMDA. We observed efficient modification of 14 of 15 sites with TGTV PAMs ( Supplementary  Fig. 3e ) and a range of editing activities across the other 82 sites harboring 25 additional PAMs ( Supplementary Fig. 3f ). Comparison of the mean PAMDA log 10 k and the mean human cell targeting values across the same PAMs showed a strong correlation for most PAMs ( Supplementary Fig. 3g ), suggesting that PAMs with a PAMDA log 10 k of -2.25 or higher were potentially targetable in human cells. PAMs accessible with E174R/S542R/K548R were binned into confidence tiers based on consistency between PAMDA and human cell experiments ( Fig. 1e , Supplementary Fig. 3h and Supplementary  Table 2 ; see Supplementary Results). Differences in activities across sites with the E174R/S542R/K548R variant could not be attributed to PAM or spacer sequence features ( Supplementary Fig. 3i -n; see Supplementary Results ). Taken together, our combined analyses illustrate that the E174R/S542R/K548R variant, henceforth referred to as enhanced AsCas12a (enAsCas12a), expands targeting range by approximately sevenfold (Fig. 1f ).
While characterizing our different engineered AsCas12a variants, we noticed that certain substitutions were associated with increased editing activities in human cells ( Fig. 1a and Supplementary Fig. 1d ). To assess this improvement more comprehensively, we compared the gene modification activities of wild-type AsCas12a, E174R/ S542R and enAsCas12a across 21 endogenous gene sites with canonical PAMs ( Supplementary Fig. 4a ). Compared to wild-type AsCas12a, both variants were on average nearly twofold more effective at modifying sites with TTTV PAMs (Fig. 2a ).
Given the enhanced gene editing efficiencies observed with enAsCas12a, we speculated that this variant might also exhibit improved activity at lower temperatures, a property relevant for organisms that grow optimally at temperatures lower than 37 °C. Previous studies showed that AsCas12a exhibited decreased activity at lower temperatures relative to LbCas12a [20] [21] [22] . In vitro cleavage reactions of AsCas12a, LbCas12a and enAsCas12a at 37, 32 and 25 °C revealed that enAsCas12a is more active than AsCas12a at these temperatures, exhibiting activities more comparable to LbCas12a (Fig. 2b ). Systematic examination of variants harboring all possible combinations of the E174R, S542R and K548R substitutions revealed that the improvements in cleavage efficiency with enAsCas12a at lower temperatures were largely attributable to E174R and to a lesser extent to S542R (Fig. 2b) .
To determine whether the increased activity phenotype of enAs-Cas12a might be transferable to other AsCas12a variants, we added the E174R substitution to the previously described RVR and RR PAM recognition variants 3 to create enRVR and enRR, respectively. Comparison of the activities of wild-type AsCas12a, enAsCas12a, RVR, enRVR, RR and enRR across 11 sites with TTTN PAMs in human cells revealed that the original RVR and RR variants have similar or weaker activities compared to wild-type AsCas12a ( Supplementary Fig. 4b ). Furthermore, the enRVR and enRR variants generally showed more than twofold higher activities than RVR and RR, albeit with lower activities compared to enAsCas12a ( Fig. 2c ). Comparison of the editing activities of RVR and enRVR on 14 endogenous gene sites bearing TATN PAMs ( Supplementary  Fig. 4c ) again showed an approximately twofold improvement with enRVR relative to the original RVR variant ( Fig. 2d ). Similarly, we examined the activities of enRR and RR in human cells on 29 sites bearing TYCN PAMs ( Supplementary Fig. 4d ) and found that enRR showed an average of 1.5-fold improved efficiency compared to RR ( Fig. 2e ). Importantly, the enRVR and enRR variants retained similar PAM preferences to their parental RVR and RR variants ( Fig. 2f and Supplementary Fig. 4e ). Collectively, enAsCas12, enRVR, and enRR exhibit improved activities and can target an expanded range of sequences compared to wild-type AsCas12a ( Supplementary Fig. 4f and Supplementary Table 2 ).
We next sought to assess whether enAsCas12a could improve the efficiency of various Cas12a-based applications. One potential advantage of Cas12a enzymes is their RNase activity, which enables the processing of individual crRNAs from a poly-crRNA transcript 11 and simplifies multiplex targeting in cells [12] [13] [14] . We compared the activities of AsCas12a, enAsCas12a and LbCas12a programmed with poly-crRNA arrays targeted to three endogenous genes in human cells ( Fig. 3a-c) . In all cases, we observed comparable or higher editing with enAsCas12a relative to AsCas12a and LbCas12a. We also designed multiplex arrays encoding two sets of proximally targeted crRNAs to generate small genomic deletions. Pairs of crRNAs were expressed from either poly-crRNA transcripts or pools of single crRNA plasmids, and we again observed comparable or improved deletion efficiencies with enAsCas12a relative to AsCas12a and LbCas12a (Fig. 3d ).
Cas12a has also been used for epigenetic editing of endogenous human and plant genes by fusing DNase-inactive Cas12a (dCas12a) to heterologous effectors 13, 21, [23] [24] [25] . We found that a fusion of DNaseinactive enAsCas12a to the synthetic VPR activation domain 26 (denAsCas12a-VPR) outperformed analogous dAsCas12a-, dLb-Cas12a- 13 and dSpCas9 26 -based VPR fusions (Supplementary Results and Supplementary Fig. 5a -f). Additional experiments comparing dAsCas12a-, denAsCas12a-and dLbCas12a-VPR targeted to the promoters of three endogenous human genes revealed that the most potent gene activation (range of 10-to 10,000-fold upregulation) was consistently achieved with the denAsCas12a-VPR fusion using pools of crRNAs targeted to sites with canonical ( Fig. 3e ) or non-canonical PAMs (Fig. 3f ,g).
Cas12a enzymes have recently been adapted for base editing to induce targeted C-to-T alterations 27 . Base editors (BEs) consist of cytosine deaminases and uracil glycosylase inhibitor domains fused to nickase versions of Cas9 or DNase-inactive forms of LbCas12a [27] [28] [29] [30] . Comparable DNase-inactive AsCas12a-BEs (AsBEs) have been reported as being minimally active 27 . To determine whether the enhanced activities of enAsCas12a could enable efficient base editing, we compared four different denAsCas12a base-editor fusions (enAsBE1.1-1.4; Supplementary Fig. 6a ) to two analogous dAsCas12a constructs (AsBE1.1 and 1.4). Consistent with previous reports 27 , we observed minimal (< 2%) C-to-T editing with AsBEs across all Cs for seven of eight sites in human cells with a maximum of 6% editing on the eighth site ( Fig. 3h and Supplementary  Table 3 ). However, enAsBE fusions exhibited substantially improved C-to-T editing across the same eight sites (range of 2-34% editing; Fig. 3h and Supplementary Fig. 6b ). Assessment of two analogous dLbCas12a base editors (LbBE1.1 and 1.4) revealed levels of C-to-T editing comparable to those of enAsBEs (range of 2-19% C-to-T editing; Fig. 3h ,i). Similar to previous studies of SpCas9-BEs, GC motifs were edited less efficiently by Cas12a-BEs than AC, CC or TC motifs ( Supplementary Fig. 6c ). Additionally, C-to-T conversion was the predominant edit outcome with enAsBEs and LbBEs ( Supplementary Fig. 6d ), while levels of insertion and deletion Letters NATuRE BIOTECHNOlOgy mutations (indels) for Cas12a-BEs were low presumably due to DNase inactivation of the nuclease ( Supplementary Fig. 6e ).
Because enAsCas12a targets an expanded number of PAMs, we assessed the genome-wide specificity of this variant in human cells using GUIDE-seq 31 (Supplementary Fig. 7a ). Experiments performed with four crRNAs targeted to sites harboring TTTV PAMs ( Supplementary Fig. 7b -d) showed few detectable off-targets with wild-type AsCas12a by GUIDE-seq but additional off-targets with enAsCas12a ( Fig. 4a , Supplementary Fig. 7e , and Supplementary Table 4 ). Several of the off-targets observed only with enAsCas12a were sites that harbored non-canonical PAMs, were previously identified as off-target sites in GUIDE-seq experiments performed with LbCas12a and the same crRNAs 10 , or contained mismatches in spacer positions known to be tolerant of nucleotide substitutions by AsCas12a 10, 16, 32 .
To attempt to improve the specificity of enAsCas12a, we employed a strategy that we and others previously used to engineer high-fidelity variants of SpCas9 (refs. [33] [34] [35] ). Using structureguided design, we created a series of AsCas12a and enAsCas12a variants with substitutions in amino acid residues expected to make non-specific contacts to DNA 17 (see Supplementary Results and Supplementary Fig. 8a,b ). Among the variants we examined, we found that enAsCas12a-N282A exhibited the greatest improvement in single mismatch intolerance while retaining on-target activity similar to enAsCas12a ( Supplementary Fig. 8b ). Comparison of the two nucleases using the PAMDA revealed nearly identical PAM preference profiles ( Supplementary Fig. 8c-e ), suggesting that the N282A substitution does not substantially alter targeting range.
We compared the genome-wide specificities of enAsCas12a and enAsCas12a-N282A using GUIDE-seq performed with the same four TTTV PAM crRNAs described above. The introduction of the N282A substitution into enAsCas12a reduced both the number of offtarget sites and the magnitude of GUIDE-seq read counts at off-target sites for three of the four crRNAs ( Fig. 4a and Supplementary Fig. 7e ). Additional GUIDE-seq experiments using 10 crRNAs targeted to sites with non-canonical PAMs again revealed that enAsCas12a-N282A reduced the number of off-target sites and GUIDE-seq read counts compared to enAsCas12a ( Fig. 4b and Supplementary Fig. 7f ). Based on these results, we conclude that the N282A substitution can be combined with enAsCas12a to generate an enhanced high-fidelity AsCas12a variant, which we refer to as enAsCas12a-HF1.
To more thoroughly determine if the N282A substitution impacts on-target activity, we compared enAsCas12a and enAsCas12a-HF1 using several methods. We first performed in vitro cleavage assays to assess temperature tolerance, which revealed similar cleavage profiles among enAsCas12a, enAsCas12a-HF1 and LbCas12a at 37, 32 and 25 °C ( Supplementary Fig. 9a ). Next, we compared the on-target activities of both AsCas12a variants when delivered by plasmid electroporation into human U2OS cells on sites with canonical and non-canonical PAMs ( Supplementary Fig. 9b ,c, respectively). These experiments revealed similar on-target activities for enAsCas12a and enAsCas12a-HF1 across six sites with TTTV PAMs, where both variants again exhibited approximately twofold improved editing compared to wild-type AsCas12a (Fig. 4c ). Additionally, we observed comparable activities of enAsCas12a and enAsCas12a-HF1 on 17 target sites with various non-canonical PAMs (Fig. 4d ). Taken together, these results show that the introduction of N282A does not abrogate the improved targeting range, temperature tolerance or higher gene editing activities of enAsCas12a-HF1.
Because the delivery of nucleases as RNP complexes offers advantages for research use and potentially therapeutic applications [36] [37] [38] , we assessed whether our enhanced variants could be transfected as Supplementary Fig. 4a ); NS, P > 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (Wilcoxon signed-rank, two-tailed; P values in Supplementary Table 8 ). b, Quantification of time-course in vitro cleavage reactions of Cas12a orthologs and variants on linearized plasmid substrates encoding the PAMDA site 1 target, conducted at 37, 32 and 25 °C (left, middle and right panels, respectively). Curves were fit using a one-phase exponential decay equation; mean and error bars represent s.e.m. for n = 3. c-e, Summaries of the activities of wild-type AsCas12a and variants across sites encoding TTTN PAMs (c; n = 11), TATN PAMs (d; n = 14) and TYCN PAMs (e; n = 29) (see also Supplementary Fig. 4b-d , respectively); mean activity is shown with a black line; NS, P > 0.05; *P < 0.05; **P < 0.001 (Wilcoxon signed-rank, two-tailed; P values in Supplementary  Table 8 ). f, Scatterplots of the PAMDA determined rate constants for each NNNN PAM to compare the PAM preferences of AsCas12a variants (RVR to enRVR, left panel; RR to enRR, right panel). Variants encode the following substitutions: enAsCas12a, E174R/S542R/K548R; RVR, S542R/K548V/N552R; enRVR, E174R/S542R/K548V/N552R; RR, S542R/K607R; enRR, E174R/S542R/K607R.
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RNPs into HEK293T and primary human T cells. We performed initial experiments with Cas12a RNPs in HEK293T cells to compare gene disruption efficiencies of wild-type AsCas12a, enAsCas12a and enAsCas12-HF1 targeted to sites with canonical and non-canonical PAMs (see Supplementary Results and Supplementary Fig. 9d,e ). We then examined the activities of the same RNP complexes when delivered to primary human T cells ( Supplementary Fig. 9f ) and found that enAsCas12a and enAsCas12a-HF1 both showed PAM Target gene f 50,000
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10,000 (CAG, c) . The activities at three separate loci were assessed by T7E1 assay using the same genomic DNA samples; mean, s.e.m. and individual data points shown for n = 3. d, Assessment of editing efficiencies with AsCas12a, enAsCas12a and LbCas12a when using pooled crRNA plasmids or multiplex crRNA arrays expressing two crRNAs targeted to nearby (~100 bp) genomic loci. Activities assessed by T7E1 assay; mean, s.e.m., and individual data points shown for n = 4. e-g, Activation of endogenous human genes NPY1R, HBB and AR with dCas12a-VPR(1.1) fusions in HEK293 cells using pools of three crRNAs targeted to canonical PAM sites (e) and non-canonical PAM sites (f,g). Activities assessed by RT-qPCR and fold-changes in RNA were normalized to HPRT1 levels; mean, s.e.m. and individual data points are shown for three independent experiments (mean of three technical triplicate qPCR values); VPR, synthetic VP64-p65-Rta activation domain 26 . h, Cytosine to thymine (C-to-T) conversion efficiencies directed by dCas12a BE constructs across eight different target sites, assessed by targeted deep sequencing. The mean percentage C-to-T editing of three independent experiments was examined within a -5 to + 25 window; all Cs in this window are highlighted in green for each target site; the position of the C within the target site is indicated below the heat map. i, C-to-T editing efficiency within the 20-nt target site spacer sequence with enAsBEs and LbBEs across all eight target sites.
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a nearly twofold mean improvement in on-target editing on sites with TTTV PAMs compared to wild-type AsCas12a (Fig. 4e ). Furthermore, enAsCas12a and enAsCas12a-HF1 also exhibited editing on sites with non-canonical PAMs compared with negligible editing by wild-type AsCas12a on these same sites (Fig. 4e) .
The enhanced AsCas12a variants described herein substantially improve the targeting range, on-target activities and fidelity of Cas12a nucleases, which are properties that are important for multiplex gene editing, epigenetic editing, cytosine base editing and gene knockout in primary human T cells. Our in vitro PAMDA and human cell experiments suggest that enAsCas12a can target approximately 1 in every 6 bp of DNA, a roughly sevenfold improvement compared to most Cas12a orthologs. enAsCas12a also exhibits superior ontarget activity relative to wild-type AsCas12a, increasing editing efficiencies by approximately twofold on sites with canonical TTTV PAMs in two cell lines and in primary human T cells. The enhanced enRVR and enRR variants also show improved activities compared to their parental variants. Our results provide an important proofof-concept that the on-target potency of CRISPR enzymes can be augmented through engineering, a strategy that may be extensible to other CRISPR nucleases. Future structural studies will be helpful to characterize the roles of the substitutions in our AsCas12a variants (see Supplementary Discussion) , and additional work may be required to determine whether the potency of enAsCas12a and enAsCas12a-HF1 RNPs are sufficient for therapeutic applications. In sum, the superior properties of the enhanced Cas12a enzymes described herein enable a wide range of applications that should encourage more widespread adoption of this class of nucleases.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability, and associated accession codes are available at https://doi.org/10.1038/ s41587-018-0011-0. Supplementary Fig. 7f ). na, not assessed. c,d, Summaries of the on-target activities of wild-type, enAsCas12a and enAsCas12a-HF1 across sites encoding TTTV PAMs (c; n = 6) or enAsCas12a and enAsCas12a-HF1 on non-canonical PAMs (d; n = 17) (see Supplementary Fig. 9b ,c, respectively). e, Assessment of the gene editing activities of AsCas12a, enAsCas12a and enAsCas12a-HF1 on-target sites harboring TTTV PAMs or non-canonical PAMs (n = 5 and 6, respectively) in primary human T cells when delivered as RNPs (see Supplementary Fig. 9f ). For c-e, percentage modified assessed by T7E1 assay, with the mean shown by black bars and where each point is the mean of three independent experiments (see Supplementary Fig. 9b ,c,f); NS, P > 0.05; *P < 0.05 (Wilcoxon signedrank, two-tailed; P values in Supplementary Table 8 ). Variants encode the following substitutions: enAsCas12a, E174R/S542R/K548R; enAsCas12a-HF1, E174R/N282A/S542R/K548R.
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Methods Plasmids and oligonucleotides. New plasmids described in this study have been deposited with the non-profit plasmid repository Addgene (http://www. addgene.org/crispr-cas). Descriptions and sequences of plasmids can be found in Supplementary Table 5 and the Supplementary Information, respectively. The  target site sequences for crRNAs and oligonucleotide sequences are available  in Supplementary Tables 6 and 7 , respectively. Human expression plasmids for wild-type AsCas12a, LbCas12a, FnCas12a and MbCas12a (SQT1659, SQT1665, AAS1472 and AAS2134, respectively) were generated by sub-cloning the nuclease open-reading frames from plasmids pY010, pY016, pY004 and pY014, respectively (Addgene plasmids 69982, 69988, 69976 and 69986; gifts from F. Zhang) into the NotI and AgeI sites of pCAG-CFP (Addgene plasmid 11179; a gift from C. Cepko). Protein expression plasmids were generated by cloning the human codon-optimized open-reading frame of AsCas12a and the bacterial codonoptimized LbCas12a open-reading frame (from Addgene plasmid 79008; a gift from Jin Soo Kim) into the NcoI and FseI sites of pET28b-Cas9 (Addgene plasmid 47327; a gift from A. Schier) to generate BPK3541 and RTW645, respectively. All Cas12a variants, activator constructs and base-editor fusions were generated via standard molecular cloning and isothermal assembly. Human cell expression plasmids for Cas12a crRNAs were generated by annealing and ligating oligonucleotides corresponding to spacer sequence duplexes into BsmBI-digested BPK3079, BPK3082 (ref. 10 ), BPK4446 and BPK4449 for U6 promoter-driven transcription of As, Lb, Fn and MbCas12a crRNAs, respectively. Substrate plasmids for in vitro cleavage reactions were generated by cloning target sites into the EcoRI and SphI sites of p11-lacY-wtx1. Plasmids for in vitro transcription of Cas12a crRNAs were generated by annealing and ligating oligonucleotides corresponding to spacer sequence duplexes into BsaI-digested MSP3491 and MSP3495 for T7 promoter-driven transcription of As and LbCas12a crRNAs, respectively.
Cell culture conditions and isolation of primary human T cells. Human U2OS
(from T. Cathomen, Freiburg) were cultured in Advanced Dulbecco's Modified Eagle Medium supplemented with 10% heat-inactivated FBS (HI-FBS), 1% penicillin/streptomycin and 2 mM GlutaMAX. HEK293 cells (Invitrogen) and HEK293T (ATCC) cells were cultured in DMEM supplemented with 10% HI-FBS and 1% penicillin/streptomycin (with the exceptions that HEK293 cells cultured for experiments analyzed by quantitative PCR with reverse transcription (RT-qPCR) had 0.4% penicillin/streptomycin and HEK293 cells cultured for experiments analyzed by ELISA were also supplemented with 2 mM GlutaMAX). Primary human T cells were cultured in RPMI1640 supplemented with 10% HI-FBS, 1% penicillin/streptomycin, 1% GlutaMAX, 1% non-essential amino acids, 1% sodium pyruvate, 5 mM HEPES, 50 μ M 2-mercaptoethanol (Millipore Sigma), and 20 IU ml -1 IL-2 (Peprotech). 1.5% M form phytohemagglutinin were added to T cell cultures on thaw. Cell culture reagents were purchased from Thermo Fisher Scientific unless otherwise noted, and cells were grown at 37 °C in 5% CO 2 . Media supernatant was analyzed biweekly for the presence of mycoplasma using MycoAlert PLUS (Lonza), and cell line identities were confirmed by STR profiling (ATCC). No commonly misidentified cell lines were used. Unless otherwise indicated, negative control transfections included Cas12a and U6-null plasmids. Primary human T cells were isolated from source leukocytes purchased from the Massachusetts General Hospital Blood Transfusion Service with prior approval from the Partners Subcommittee on Human Studies. T cells were enriched from whole blood using RosetteSep Human T Cell Enrichment Cocktail (STEMCELL Technologies) per manufacturer instructions. Following T cell enrichment, 15 ml of RosetteSep-treated blood was mixed 1:1 with PBS containing 2% HI-FBS and then gently overlaid onto 15 ml of Ficoll-Paque Plus (Millipore Sigma). Phase-separated suspensions were centrifuged at 1,200g for 20 min with no brake applied. Following centrifugation, the buffy coat fraction was removed and washed twice with 45 ml of PBS supplemented with 2% HI-FBS. Cells were centrifuged at 300g for 10 min with minimum brake following each wash. Washed T cells were resuspended in 90% HI-FBS and 10% DMSO (ATCC) and aliquots of approximately 40 million cells were cryopreserved.
Assessment of gene and base editing by T7E1 or deep sequencing.
For nuclease and base-editor experiments in U2OS cells, Cas12a and crRNA expression plasmids (580 ng and 250 ng, respectively) were electroporated into approximately 2 × 10 5 U2OS cells via the DN-100 program with the SE Cell Line Nucleofector Kit using a 4D-Nucleofector (Lonza). For RNP experiments in HEK293T cells, approximately 10 5 cells were seeded in a 24-well plate about 24 h before transfection. RNPs were complexed by mixing 70 pmol of Cas12a and 140 pmol crRNA (Integrated DNA Technologies) in 50 μ l Opti-MEM at room temperature for 15 min. Next, RNPs were mixed with with 4 μ l CRISPRMAX and 2.5 μ l Cas9 Plus reagent (Invitrogen), and then carefully dropped into existing cell culture media for transfection. For experiments in T cells, after two days in culture, Cas12a RNPs (70 pmol of Cas12a and 140 pmol crRNA) were electroporated into approximately 3 × 10 5 cells via the DN-100 program with the P3 Primary Cell Nucleofector Kit using a 4D-Nucleofector.
Genomic DNA (gDNA) was extracted approximately 72 or 120 h postelectroporation (for nuclease or base-editing experiments, respectively) using the Agencourt DNAdvance Nucleic Acid Isolation Kit (Beckman Coulter), or by custom lysis and paramagnetic bead extraction. Paramagnetic beads were prepared similar to as previously described 39 (GE Healthcare Sera-Mag SpeedBeads from Fisher Scientific, washed in 0.1X TE and suspended in 20% PEG-8000 (w/v), 1.5 M NaCl, 10 mM Tris-HCl pH 8, 1 mM EDTA pH 8 and 0.05% Tween20). For cell lysis, media supernatant was removed, a 500 μ l PBS wash was performed, and the cells were treated with 200 μ l lysis buffer (100 mM Tris-HCl pH 8.0, 200 mM NaCl, 5 mM EDTA, 0.05% SDS, 1.4 mg ml -1 Proteinase K (New England Biolabs; NEB), and 12.5 mM DTT) for 12-20 h at 55 °C. To extract gDNA, the lysate was combined with 165 μ l paramagnetic beads, mixed thoroughly, incubated for 5 min, separated on a magnetic plate and washed three times with 70% EtOH, allowed to dry for 5 min and eluted in 65 μ l elution buffer (1.2 mM Tris-HCl pH 8.0). Genomic loci were amplified by PCR with Phusion Hot Start Flex DNA Polymerase (NEB) using approximately 100 ng of gDNA as a template and the primers listed in Supplementary Table 7 . Following analysis on a QIAxcel capillary electrophoresis machine (Qiagen), PCR products were purified with paramagnetic beads.
For nuclease experiments, the percentage modification of endogenous human target sites was determined by T7 Endonuclease I (T7EI) assays, similar to as previously described 40 . The T7E1 assay was selected to quantify relative differences in activities between Cas12a nucleases because it has previously been shown that the T7E1 assay is effective at detecting indels greater than 1 nt (refs. 41, 42 ), consistent with indel profiles that are commonly observed with Cas12a nucleases 16, 43 . Briefly, 200 ng of purified PCR products were denatured, annealed and digested with 10 U T7EI (NEB) at 37 °C for 25 min. Digests were purified with paramagnetic beads and analyzed using a QIAxcel to estimate target site modification.
For base editing experiments, targeted deep sequencing was performed essentially as previously described 33 . Dual-indexed Tru-seq libraries were generated from purified and pooled PCR products using a KAPA HTP Library Preparation Kit (KAPA BioSystems) and sequenced on an Illumina MiSeq Sequencer. Samples were sequenced to an average of 57,833 reads (minimum of 8,534 reads) per replicate and an average of 173,499 (minimum of 70,022) per triplicate condition. Nucleotide substitutions and insertion or deletion mutations (indels) were analyzed using CRISPResso2 (ref. 44 ; Supplementary Table 3) , with an additional custom analysis performed to examine indel percentages (defined as [reads with an indel and/or substitution -substitution-only reads] / total reads × 100), in a 44-nt window encompassing the -14 to + 30 region of each target site (an additional 10 nt upstream of the 4-nt PAM and 10 nt downstream of the 20-nt spacer sequence).
Gene activation experiments.
For experiments with crRNAs or sgRNAs targeting the VEGFA promoter, 1.6 × 10 5 HEK293 cells per well were seeded in 24-well plates roughly 24 h before transfection with plasmids encoding Cas12a or Cas9 activators and pools of crRNAs or sgRNAs (750 ng and 250 ng, respectively), 1.5 μ l TransIT-LT1 (Mirus) and Opti-MEM to a total volume of 50 μ l. The cell culture media were changed 22 h post-transfection, and aliquots of the media supernatant were collected 44 h post-transfection to determine VEGFA concentration using a Human VEGF Quantikine ELISA Kit (R&D Systems).
For experiments with crRNAs targeting the AR, HBB or NPY1R promoters, 8.6 × 10 4 HEK293 cells per well were seeded in 12-well plates roughly 24 h before transfection with 750 ng Cas12a activator expression plasmid, 250 ng crRNA plasmid pools, 3 μ l TransIT-LT1 (Mirus) and 100 μ l Opti-MEM. Total RNA was extracted from the transfected cells 72 h post-transfection using the NucleoSpin RNA Plus Kit (Clontech). complementary DNA synthesis using a High-Capacity RNA-to-cDNA kit (Thermo Fisher Scientific) was performed with 250 ng of purified RNA, and 3 μ L of 1:20 diluted cDNA was amplified by RT-qPCR using Fast SYBR Green Master Mix (Thermo Fisher Scientific) and the primers listed in Supplementary Table 7 . RT-qPCR reactions were performed on a LightCycler480 (Roche) with the following cycling program: initial denaturation at 95 °C for 20 s followed by 45 cycles of 95 °C for 3 s and 60 °C for 30 s. If sample amplification did not reach the detection threshold after 35 cycles, cycles to threshold (C t ) values were considered as 35 due to C t fluctuations typical of transcripts expressed at very low levels. Gene expression levels over negative controls experiments (Cas12a activator and empty crRNA plasmids) were normalized to the expression of HPRT1. GUIDE-seq. GUIDE-seq experiments were performed as previously described. Briefly, U2OS cells were electroporated as described above but including 100 pmol of the double-stranded oligodeoxynucleotide (dsODN) GUIDE-seq tag. Restriction-fragment length polymorphisms (RFLP) assays (performed as previously described 45 ) and T7E1 assays (as described above) were performed to assess GUIDE-seq tag integration and on-target modification percentages, respectively. GUIDE-seq libraries were sequenced using an Illumina MiSeq sequencer and data was analyzed using GUIDE-seq v1.1 (ref. 46 ) with an NNNN PAM, a 75-bp window, and allowing up to nine mismatches before downstream data processing ( Supplementary Table 4 ). High-confidence, cell-type-specific, single-nucleotide polymorphisms were identified using SAMTools. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Nucleic acids samples were visualized using Qiaxcel ScreenGel Software (v1.4 and v1.5). Sequencing data was acquired using an Illumina MiSeq machine.
Data analysis
Nucleic acids samples were analyzed using Qiaxcel ScreenGel Software (v1.4 and v1.5). Data visualization was performed using GraphPad Prism 7.0c. GUIDE-seq data was analyzed with guideseq software v1.1 (https://github.com/aryeelab/guideseq), and amplicon sequencing data was analyzed with CRISPResso (https://github.com/lucapinello/CRISPResso). Custom scripts to analyze PAM depletion data and perform targeting range calculations are available upon request.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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